시험관내 약역학 감염모델을 이용한 Methicillin 내성 포도알균 실험 중 출현한 Small Colony Variants 생성억제를 위한 Arbekacin의 효과

참고문헌 (40)

1. "Emergence of methcillin- resistant Staphylococcus aureus with intermediate glycopeptide resistance:clinical significance and treatment options", 61, pp.1~7 (2001)
2. "The evolutionary history of methicillin-resistant Staphylococcus aureus(MRSA)", 99, pp.7687~7692 (2002)
3. "Methicillin resistant Staphylococcus aureus(MRSA)in the intensive care unit", 78, pp.385~392 (2002)
4. "Antimicrobial resistance among gram-positive organisms in the intensive care unit", 9, pp.403~412 (2003)
5. "Persistent and relapsing infections associated with small colony variants of Staphylococcus aureus", 20, pp.95~102 (1995)
6. "Persistent wound infection after herniotomy associated with small colony variants of Staphylococcus aureus", 28, pp.53~54 (2000)
7. "Small colony variants of Staphylococcus aureus and pacemaker-related infection", 9, pp.1316~1318 (2003)
8. "Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of Staphylococcus aureus", 41, pp.48~52 (2005)
9. "Staphylococcal small colony variants have novel mechanisms for antibiotic resistance", 27, pp.68~74 (1998)
10. "Small colony variants in staphylococcal infections:diagnostic and therapeutic implications", 27, pp.419~423 (1998)
11. "Staphylococcus aureus small colony variants,electron transport and persistent infections", 14, pp.117~122 (2000)
12. "A case of methicillin- resistant Staphylococcus aureus small colony variants(SCVs)isolated from urine of a patient with persistent and relapsing bladder stone", 3, pp.75~78 (2000)
13. "A case of small colony variants(SCVs)of Staphylococcus aureus from sputum of a patient with chronic renal failure", 6, pp.164~167 (2003)
14. "In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus", 36, pp.37~41 (2000)
15. "Antimicrobial activities of arbekacin against clinical isolates of Staphylcoccus aureus and coagulase-negative staphylocuccus species", 33, pp.254~260 (2001)
16. "In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea", 48, pp.1124~1127 (2004)
17. "Performance standards for antimicrobial susceptibility testing; 12th informational suppleme", pp.12~ (2002), National Committee for Clinical Laboratory Standards
18. "Report of the Committee for Japanese Standards for Antimicrobial Susceptibility Testing for Bacteria", 38, pp.102~5 (1990)
19. "Historical review of in vitro models", 15, pp.99~102 (1985)
20. "Synergism between ceftriaxone and amikacin against a intermediately resistant Klebsiella pneumoniae strain tested by an in vitro pharmacokinetic model", 7, pp.40~48 (1999)
21. "Determination of antibiotic effect in an in vitro pharmacodynamic model:comparison with an established animal model of infection", 46, pp.3574~3579 (2002)
22. "Arbekacin", 5, pp.227~230 (1995)
23. "Two compartment kinetic model with multiple artificial capillary units", 15, pp.131~7 (1985)
24. "Pharmacokinetic considerations for the setting of in vitro models", 15, pp.85~97 (1985)
25. "Susceptibility testing of antimicrobials in liquid media" (1996)
26. "Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis", 177, pp.1023~1029 (1998)
27. "Comparative studies of the bactericidal,morphological and postantibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus", 39, pp.471~476 (1997)
28. "Antimicrobial susceptibilities of glycopeptides,arbekacin and quinupristin", dalfopristin against Staphylococcus aureus isolates, 2001, pp.33, 261~266
29. "In vitro activities of daptomycin and gentamicin alone and", or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model, 2000, pp.44, 1925~1929
30. "Efficacies of vancomycin,arbekacin,and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model", 47, pp.3768~3773 (2003)
31. "Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methcillin-resistant Staphylococcus aureus in an in vitro pharmacodymamic infection model", 49, pp.302~308 (2005)
32. "Molecular mechanism for enhancement of arbekacin resistance in a methicillin-resistant Staphylococcus aureus", 546, pp.401~406 (2003)
33. "Current use for old antibacterial agents:polymyxins,rifampin,and aminoglycosides", 18, pp.669~389 (2004)
34. "The utility and dosage and administration of arbekacin in patients with MRSA infection", 12, pp.120~127 (1996)
35. "Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces", 39, pp.603~608 (1997)
36. "Phenotypic switching of antibiotic resistance circumvents permanent costs in Staphylococcus aureus", 11, pp.1810~1814 (2001)
37. "Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus", 293, pp.427~435 (2003)
38. "Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis", 25, pp.1250~1251 (1997)
39. "Once-daily aminoglycoside dosing in immunocompetent adults:a meta- analysis", 124, pp.717~725 (1996)
40. "Pharmacodynamics and dosing of aminoglycosides", 17, pp.503~528 (2003)

관련 논문AI추천